AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33877063 — intervention group
Group type: COMPARATOR
Intervention: AlloDerm RTU
Number of subjects: 230
Study 33877063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 230
Study 35413866 — intervention group
Group type: EXPERIMENTAL
Intervention: Current socket plus 8 different check sockets with designed changes in structural measurements
Number of subjects: 0
Study 35413866 — intervention group
Group type: EXPERIMENTAL
Intervention: New quantitative design method
Number of subjects: 0
Study 35413866 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 32448331 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention team (psychiatric‐mental health advanced practice nurse and clinical social worker)
Number of subjects: 1790
Study 34808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-Arterial Nimodipine Infusion (IANI)
Number of subjects: 68
Study 34808678 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Control)
Number of subjects: 68
Study 32764545 — intervention group
Group type: EXPERIMENTAL
Intervention: MUAC-O (low MUAC only)
Number of subjects: 1489
Study 32764545 — intervention group
Group type: COMPARATOR
Intervention: WLZ-O (low WLZ only)
Number of subjects: 1489
Study 33721300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting thigh position with leg bent
Number of subjects: 8
Study 33721300 — intervention group
Group type: COMPARATOR
Intervention: Sitting thigh position with leg straight
Number of subjects: 8
Study 33721300 — intervention group
Group type: EXPERIMENTAL
Intervention: Laying position with leg bent first
Number of subjects: 8
Study 33721300 — intervention group
Group type: COMPARATOR
Intervention: Laying position with leg straight first
Number of subjects: 8
Study 33721300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting arm position with arm bent
Number of subjects: 8
Study 33721300 — intervention group
Group type: COMPARATOR
Intervention: Sitting arm position with arm straight
Number of subjects: 8
Study 35710164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit-rich diet (FRD) with at least 4 servings of fruits daily
Number of subjects: 80
Study 35710164 — intervention group
Group type: COMPARATOR
Intervention: Control group with less than 2 servings of fruits/day
Number of subjects: 80
Study 34170090 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody against IBV M41 S1 protein
Number of subjects: 0
Study 34170090 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect competitive enzyme-linked immunosorbent assay
Number of subjects: 0
Study 32756593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Focus Condition (TFC)
Number of subjects: 67
Study 32756593 — intervention group
Group type: COMPARATOR
Intervention: Body Focus Condition (BFC)
Number of subjects: 67
Study 35475721 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education regarding milk expression
Number of subjects: 61
Study 35475721 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 61
Study 34704710 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LIDO group)
Number of subjects: 91
Study 34704710 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 91
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk DCIS (non-operated)
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk DCIS (non-operated)
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk DCIS (overall)
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk DCIS (overall)
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DCIS cohort
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk DCIS (surgery not received)
Number of subjects: 1391
Study 32713775 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk DCIS (surgery not received)
Number of subjects: 1391
Study 33256727 — intervention group
Group type: EXPERIMENTAL
Intervention: Museum-based arts
Number of subjects: 34
Study 33256727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based arts
Number of subjects: 34
Study 33256727 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based conventional education
Number of subjects: 34
Study 37217585 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring using wearable devices
Number of subjects: 500
Study 37217585 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring using smartphones
Number of subjects: 500
Study 37217585 — intervention group
Group type: COMPARATOR
Intervention: Standard model (data collected up to discharge)
Number of subjects: 500
Study 37217585 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced model (standard model + RPM data)
Number of subjects: 500
Study 33121832 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine applied every 30 minutes as needed for 24 hours
Number of subjects: 118
Study 33121832 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied every 30 minutes as needed for 24 hours
Number of subjects: 118
Study 32932244 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated HFO detections with higher skewness of the curvature (skewCurve)
Number of subjects: 16
Study 32932244 — intervention group
Group type: EXPERIMENTAL
Intervention: Redacting putative false positive HFO detections
Number of subjects: 16
Study 34942092 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 34942092 — intervention group
Group type: COMPARATOR
Intervention: Second intravenous immunoglobulin
Number of subjects: 0
Study 33712841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (measured by genetic risk scores)
Number of subjects: 190573
Study 33712841 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (measured by genetic risk scores)
Number of subjects: 190573
Study 32819191 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-nap (200 mg caffeine prior to a 30 min nap)
Number of subjects: 6
Study 32819191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee prior to a 30 min nap)
Number of subjects: 6
Study 36380299 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus usual care (UC)
Number of subjects: 188
Study 36380299 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 188
Study 33088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172
Study 33088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172
Study 33088309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Number of subjects: 172
Study 33088309 — intervention group
Group type: COMPARATOR
Intervention: All groups (Vaginal, Sublingual, Oral)
Number of subjects: 172
Study 35173025 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based foot care program (6 months)
Number of subjects: 51
Study 35173025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 33753329 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21; GSK3640254 200 mg QD added on days 15 through 21
Number of subjects: 16
Study 33753329 — intervention group
Group type: COMPARATOR
Intervention: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21
Number of subjects: 16
Study 33753329 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg QD
Number of subjects: 16
Study 35131614 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingman-Connect Program (W-CP)
Number of subjects: 1485
Study 35131614 — intervention group
Group type: COMPARATOR
Intervention: Active control (stress management training)
Number of subjects: 1485
Study 33736819 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730
Study 33736819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 32700995 — intervention group
Group type: EXPERIMENTAL
Intervention: NaI (20 mg/kg, PO, 2 doses 72 hours apart; n = 211)
Number of subjects: 434
Study 32700995 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (216)
Number of subjects: 434
Study 35670064 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 2 mA tDCS (N = 14)
Number of subjects: 28
Study 35670064 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (N = 14)
Number of subjects: 28
Study 35670064 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized reverse‐calculation doses
Number of subjects: 28
Study 32321707 — intervention group
Group type: EXPERIMENTAL
Intervention: BaSAT intervention
Number of subjects: 100
Study 32660872 — intervention group
Group type: EXPERIMENTAL
Intervention: TTNS + VS (n = 54)
Number of subjects: 106
Study 32660872 — intervention group
Group type: COMPARATOR
Intervention: TTNS (n = 52)
Number of subjects: 106
Study 33472996 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar combined with chemotherapy (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Number of subjects: 44
Study 33472996 — intervention group
Group type: COMPARATOR
Intervention: Control group (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Number of subjects: 44
Study 33273297 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sample of Medicare beneficiaries with a cutoff of 6 patients shared between 2 primary care providers
Number of subjects: 100
Study 33273297 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% data within a small area geographic boundary (PCSAs)
Number of subjects: 100
Study 33273297 — intervention group
Group type: COMPARATOR
Intervention: 20% sample of Medicare beneficiaries
Number of subjects: 100
Study 33273297 — intervention group
Group type: COMPARATOR
Intervention: 100% data from statewide
Number of subjects: 100
Study 35731506 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CR (2 weeks after sternotomy)
Number of subjects: 158
Study 35731506 — intervention group
Group type: COMPARATOR
Intervention: Usual-care CR (6 weeks after sternotomy)
Number of subjects: 158
Study 33075711 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 102
Study 33075711 — intervention group
Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 102
Study 36403898 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic and resistance training (HIART) program
Number of subjects: 82
Study 36403898 — intervention group
Group type: COMPARATOR
Intervention: Control (60-min education session)
Number of subjects: 82
Study 33587443 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg daily)
Number of subjects: 81
Study 33587443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 36219142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (15-minute sessions in the morning/evening for 3 days)
Number of subjects: 64
Study 36219142 — intervention group
Group type: COMPARATOR
Intervention: Pump milking (control group, only milked in the mornings and evenings)
Number of subjects: 64
Study 33712030 — intervention group
Group type: EXPERIMENTAL
Intervention: iPSC-MSCs
Number of subjects: 40
Study 33712030 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSCs
Number of subjects: 40
Study 33712030 — intervention group
Group type: COMPARATOR
Intervention: MPS + BMSCs
Number of subjects: 40
Study 33712030 — intervention group
Group type: COMPARATOR
Intervention: MPS + iPSC-MSCs
Number of subjects: 40
Study 33712030 — intervention group
Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 40
Study 36441433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for 16 weeks
Number of subjects: 46
Study 36441433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 33458819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-vaginal isosorbide mononitrate (IMN)
Number of subjects: 140
Study 33458819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 32736540 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype)
Number of subjects: 250
Study 32736540 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250
Study 32736540 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus chemotherapy
Number of subjects: 250
Study 35437881 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxygen therapy and standard of care (TOT/SOC)
Number of subjects: 29
Study 35437881 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone (SOC)
Number of subjects: 29
Study 32050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 11435
Study 32050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine-verified smoking status
Number of subjects: 11435
Study 32050232 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey-cotinine-verified smoking status (SCS)
Number of subjects: 11435
Study 34320218 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratotal resection (SpTR)
Number of subjects: 21
Study 34320218 — intervention group
Group type: COMPARATOR
Intervention: Gross total resection (GTR)
Number of subjects: 21
Study 32005283 — intervention group
Group type: EXPERIMENTAL
Intervention: Daesiho-tang (DST)
Number of subjects: 60
Study 32005283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36103844 — intervention group
Group type: EXPERIMENTAL
Intervention: Su Jok seed therapy
Number of subjects: 47
Study 36103844 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 47
Study 34227053 — intervention group
Group type: EXPERIMENTAL
Intervention: kMCT drink, BrainXpert Energy Complex
Number of subjects: 0
Study 34227053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33050905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 0
Study 33050905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32770520 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 18
Study 32770520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 35094695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose to high-density lipoprotein cholesterol (FG/HDL-C) ratio in the highest quartile
Number of subjects: 11284
Study 34139746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'‐fucosyllactose (2'FL)
Number of subjects: 75
Study 34139746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of 2'FL and lacto‐N‐neotetraose
Number of subjects: 75
Study 34139746 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 75
Study 32536270 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 135
Study 32536270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation
Number of subjects: 135
Study 32536270 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 135
Study 32536270 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (anodal, cathodal, sham)
Number of subjects: 135
Study 34216552 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 40
Study 34216552 — intervention group
Group type: EXPERIMENTAL
Intervention: IT convergence exercise
Number of subjects: 40
Study 32151753 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visit group (received enhanced clinical care, detailed home assessment, and four additional home visits over roughly one year)
Number of subjects: 263
Study 32151753 — intervention group
Group type: COMPARATOR
Intervention: Clinic-only group (received enhanced clinical care)
Number of subjects: 263
Study 36166515 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐MAC® (Macintosh style blade) videolaryngoscope
Number of subjects: 260
Study 36166515 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy using the Macintosh laryngoscope
Number of subjects: 260
Study 34340607 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1200 (thyme/ivy herbal fluid extract)
Number of subjects: 730
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 45
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 45
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-FD
Number of subjects: 45
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG
Number of subjects: 45
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-TD + ECG-FD + EMG
Number of subjects: 45
Study 33915363 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG time-domain, ECG frequency-domain, EMG, VC, SBP, pulse
Number of subjects: 45
Study 34951464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 20
Study 33721439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 136
Study 33721439 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 136
Study 33843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 210
Study 33843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised anxiety disorder, dysthymia, or mixed symptoms (cothymia)
Number of subjects: 210
Study 33843514 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with personality dysfunction at entry
Number of subjects: 210
Study 33843514 — intervention group
Group type: COMPARATOR
Intervention: No personality dysfunction at entry
Number of subjects: 210
Study 35089655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training (3 sessions/week for 6 weeks)
Number of subjects: 38
Study 35089655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training
Number of subjects: 38
Study 35089655 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study 34047835 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid platelet-rich fibrin (liquid-PRF) with bovine-derived xenograft
Number of subjects: 40
Study 34047835 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived xenograft alone
Number of subjects: 40
Study 34047835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (liquid-PRF and control)
Number of subjects: 40
Study 33234578 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment strategy using monoclonal antibodies combined with optimally sequenced chemotherapy
Number of subjects: 68
Study 33234578 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 68
Study 32236154 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterated ethyl alcohol (D-C2H5OH)
Number of subjects: 1
Study 32236154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 34146120 — intervention group
Group type: EXPERIMENTAL
Intervention: NLC‐TRE (tretinoin-loaded nano lipid carriers)
Number of subjects: 0
Study 34146120 — intervention group
Group type: COMPARATOR
Intervention: TRE cream (0.05% tretinoin cream)
Number of subjects: 0
Study 34000240 — intervention group
Group type: EXPERIMENTAL
Intervention: PCET
Number of subjects: 510
Study 34000240 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 510
Study 36205275 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy + NMES
Number of subjects: 80
Study 36205275 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 80
Study 34026698 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple exchange message
Number of subjects: 344
Study 34026698 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 344
Study 32553836 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with cow milk diet
Number of subjects: 0
Study 32553836 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with extensively hydrolyzed protein diet
Number of subjects: 0
Study 32553836 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0
Study 32553836 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants in the upper quartile for weight gain velocity
Number of subjects: 0
Study 35859328 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF as primary prophylactic therapy
Number of subjects: 130
Study 35859328 — intervention group
Group type: COMPARATOR
Intervention: Control group (rhG-CSF administered when white blood cell count was <2.0 × 10^9/L or absolute neutrophil count <1.0 × 10^9/L)
Number of subjects: 130
Study 32417822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching before delivery trials
Number of subjects: 8
Study 32417822 — intervention group
Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 8
Study 34448477 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 14 BMI-associated variants
Number of subjects: 11384
Study 34448477 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual 14 SNVs as instrumental variables
Number of subjects: 11384
Study 32404226 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 101
Study 32404226 — intervention group
Group type: COMPARATOR
Intervention: internet-delivered discussion forum (iFORUM)
Number of subjects: 101
Study 32092160 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application (app)
Number of subjects: 380
Study 32092160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study 33602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone recruitment manoeuvres (40 cm H2O peak inspiratory pressure and 20 cm H2O PEEP for 30 s)
Number of subjects: 30